Last updated: February 14, 2026
Overview
NDC 24385-0307 corresponds to the drug Zolbetuximab, a monoclonal antibody developed by Beijing ImmunoScience Co., primarily targeting gastric and colorectal cancers expressing the CLDN18.2 antigen. The drug has received various regulatory designations, including orphan drug status in the US and EU. Market entry hinges on ongoing clinical trials, with commercialization anticipated pending successful results.
Market Landscape
Target Indications and Patient Population
- Gastric and Gastroesophageal Junction Cancers: Approximately 27,000 new cases annually in the US, with a substantial unmet need in advanced stages.
- Colorectal Cancer: Over 106,000 new cases annually in the US, with a segment expressing high levels of CLDN18.2.
- Market Segments: First-line metastatic, second-line, and refractory settings.
Competitive Environment
-
Key Competitors:
- Herceptin (trastuzumab): Approved for HER2-positive gastric cancers.
- Cyramza (ramucirumab): Approved for advanced gastric cancer.
- Other CLDN18.2 therapies: IMAB362 (zenocutuzumab) in development, with a focus on CLDN18.2 as an actionable target.
-
Distinctive Factors
- Zolbetuximab's target specificity differentiates it within the monoclonal antibody space.
- Regulatory hurdles remain, with potential approval timelines around 2025-2026.
Regulatory and Development Milestones
- Phase 3 trials completed, with preliminary efficacy signals.
- Applications submitted to FDA and EMA early 2023; final decisions expected mid-2024.
- Pricing and reimbursement strategies under development, depending on trial outcomes and regulatory approval.
Pricing Benchmarks
Historical data for monoclonal antibodies in oncology suggests:
- Pricing Range: $10,000 to $15,000 per month (US prices), depending on indication, treatment duration, and payer negotiations.
- Per-Patient Annual Cost: $120,000 to $180,000.
For Zolbetuximab, pricing is projected based on this framework, adjusted for manufacturing costs, competitive landscape, and anticipated value propositions.
Price Projections (2024-2028)
| Year |
Estimated Average Monthly Price |
Assumptions and Rationale |
| 2024 |
$12,000 |
Pending regulatory approval; initial rollout; conservative pricing. |
| 2025 |
$13,000 |
Slight premium for early market entry, high unmet need. |
| 2026 |
$14,000 |
As competition emerges, pricing stabilizes, value-based negotiations. |
| 2027 |
$14,000 |
Market penetration stabilizes; volume increases offset per-unit discounts. |
| 2028 |
$13,500 |
Price adjustments reflecting payer pressures and competitive therapies. |
Revenue Potential
Assuming a peak patient base of 15,000 patients annually across indications and an average treatment duration of 6 months:
- Average annual revenue (2026):
- 15,000 patients × $14,000/month × 6 months = $1.26 billion
- Market share assumptions:
- Initial launch: 10% in year 2024.
- Reach 30-50% market penetration by 2027.
Key Risks and Uncertainties
- Clinical trial outcomes may impact approval timing.
- Price negotiations with payers can reduce gross revenue.
- Competition from emerging therapies targeting CLDN18.2.
- Manufacturing costs influence profitability margins, with monoclonal antibodies typical of $1,000–$2,000 per dose production costs.
Concluding Remarks
Zolbetuximab's market entry prospects hinge on successful clinical development and regulatory approvals. Price projections remain conservative initially, with potential for increases driven by demand and market positioning. Long-term revenues could reach over $1 billion annually post-approval, subject to competitive dynamics.
Key Takeaways
- The drug targets a high-unmet-need cancer subset, positioning it favorably for rapid adoption upon approval.
- Pricing is projected between $12,000 and $14,000 per month, aligned with comparable monoclonal antibodies.
- Peak revenues could exceed $1 billion annually, assuming broad market access and patient uptake.
- Regulatory and competitive risks are significant; approval delays or market entry barriers could diminish revenue outlook.
- Manufacturing costs and payer negotiations influence profit margins more than list prices.
FAQs
-
What is the current status of Zolbetuximab approval?
- It is in late-stage clinical trials; regulatory submissions occurred mid-2023, with approvals expected by mid-2024.
-
How does Zolbetuximab compare to existing gastric cancer therapies?
- It specifically targets CLDN18.2, offering a novel mechanism that could provide advantages over non-specific chemotherapies and existing monoclonal antibodies.
-
What factors could affect the drug’s pricing?
- Regulatory decisions, competitive therapies, payer negotiations, and manufacturing costs.
-
Which markets are the highest priority for launch?
- The US and EU represent the primary markets due to size, healthcare infrastructure, and regulatory pathways.
-
What is the potential impact of emerging therapies on Zolbetuximab’s revenue?
- New therapies targeting CLDN18.2 or alternative biomarkers could limit market share and suppress prices.
References
[1] IQVIA. "The Global Oncology Market." 2022.
[2] EvaluatePharma. "World Preview 2022: Outlook to 2027." 2022.
[3] FDA and EMA regulatory filings. 2023.
[4] Market research reports on gastric and colorectal cancers. 2022.
